These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 31685261)
1. Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy. Vasmatzis G; Liu MC; Reganti S; Feathers RW; Smadbeck J; Johnson SH; Schaefer Klein JL; Harris FR; Yang L; Kosari F; Murphy SJ; Borad MJ; Thompson EA; Cheville JC; Anastasiadis PZ Mayo Clin Proc; 2020 Feb; 95(2):306-318. PubMed ID: 31685261 [TBL] [Abstract][Full Text] [Related]
2. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast. Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364 [TBL] [Abstract][Full Text] [Related]
3. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477 [TBL] [Abstract][Full Text] [Related]
4. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958 [TBL] [Abstract][Full Text] [Related]
5. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024 [TBL] [Abstract][Full Text] [Related]
7. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling. Christgen M; Bartels S; Radner M; Raap M; Rieger L; Christgen H; Gluz O; Nitz U; Harbeck N; Lehmann U; Kreipe H Genes Chromosomes Cancer; 2019 Mar; 58(3):175-185. PubMed ID: 30520184 [TBL] [Abstract][Full Text] [Related]
8. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875 [TBL] [Abstract][Full Text] [Related]
9. Germline and Somatic Wang X; Kallionpää RA; Gonzales PR; Chitale DA; Tousignant RN; Crowley JP; Chen Z; Yoder SJ; Blakeley JO; Acosta MT; Korf BR; Messiaen LM; Tainsky MA Cancer Prev Res (Phila); 2018 Oct; 11(10):655-664. PubMed ID: 30104415 [No Abstract] [Full Text] [Related]
10. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Craig DW; O'Shaughnessy JA; Kiefer JA; Aldrich J; Sinari S; Moses TM; Wong S; Dinh J; Christoforides A; Blum JL; Aitelli CL; Osborne CR; Izatt T; Kurdoglu A; Baker A; Koeman J; Barbacioru C; Sakarya O; De La Vega FM; Siddiqui A; Hoang L; Billings PR; Salhia B; Tolcher AW; Trent JM; Mousses S; Von Hoff D; Carpten JD Mol Cancer Ther; 2013 Jan; 12(1):104-16. PubMed ID: 23171949 [TBL] [Abstract][Full Text] [Related]
16. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307 [TBL] [Abstract][Full Text] [Related]
17. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes. Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202 [TBL] [Abstract][Full Text] [Related]
18. Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells. van Agthoven T; Dorssers LC; Lehmann U; Kreipe H; Looijenga LH; Christgen M PLoS One; 2015; 10(8):e0136845. PubMed ID: 26317614 [TBL] [Abstract][Full Text] [Related]
19. Comparative genomic analysis of primary tumors and metastases in breast cancer. Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851 [TBL] [Abstract][Full Text] [Related]
20. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]